Morten Hjelmsoe offers a quick review of the development of our communication technologies- and looks forward to what’s coming next.
Morten Hjelmsoe offers a quick review of the development of our communication technologies- and looks forward to what’s coming next.
We started out taking our paper materials – our detail aids and brochures – and digitizing them. This meant that we could transport things easier but also enabled a bit of interactivity – charts would move, animations could play.
Morten Hjelmsoe
This was OK, but not really very smart. So the next step was to add some intelligence – a CRM backend to the system.
This enabled us to do some limited tracking. It was limited because it only measured message delivery – you could see what was said but learned nothing about what was actually received. And to get even this limited data, our sales force had to keep heading back to base and plugging in their devices (laptops in the early days).
To solve that, the systems went ‘into the cloud’. This kept the reps on the road. But the systems still weren’t very user friendly or appropriate to the life sciences business. So then we get a ‘pharma layer’ added to these systems.
This was fine, but basically was still CRM, so it could still only really track what we said and not what our customers thought of it. And that brings us to today.
The arrival of real CLM means that we can finally start to understand what our customers thought about our communications.
It’s interesting to me that, as we went through this technology development process, something really important emerged. Have a read back and you’ll see what there was a fundamental shift in focus from us to our customers. So rather than build a system around what suits us, we can now shape our communications around our customers.
It’s a revolution. The very best CLM technology places the customer at the center of a web of multichannel communications that that they drive. This switch from ‘push’ to ‘pull’ really is revolutionary because it means that we’re working on an individual level.
So – following a little bit of discovery – we can understand what each customer needs to know and how we can help him or her. It not only takes the guesswork out of marketing but also removes antagonism from our customer outreach.
So that’s where we are today – quietly going about a pretty fundamental revolution.
So what then about tomorrow?
The next step – and one that we can take very soon – is to empower the same process between the doctor and the patient. The industry’s shift ‘beyond the pill’ necessarily draws us further into the treatment process: creating new demands and responsibilities. But it’s not about replacing medical professionals. The very CLM technology that placed doctors in the centre of our communication can keep them there when they interact with their patients.
So for the future, we just need to expand our understanding of what the technology can do. Exciting times ahead!
Morten Hjelmsoe is the CEO and founder of Agnitio.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.